Products

Ranibizumab (TP-104CL)

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name ranibizumab. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.      

Specifications
Classify
Protein therapeutics that interfere with a molecule or organism: Other
Therapeutic
Ranibizumab
Trade Name
ranibizumab
Function
Humanized mAb fragment that binds isoforms of vascular endothelial growth factor A (VEGFA)
Examples of Clinical Use
Neovascular age-related macular degeneration
References
Synonyms
rhuFab V2

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-871-5806    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2017 Creative-Biolabs All Rights Reserved